Megan Sniecinski - Net Worth and Insider Trading

Megan Sniecinski Net Worth

The estimated net worth of Megan Sniecinski is at least $364,950 dollars as of 2024-09-21. Megan Sniecinski is the Chief Business Officer of BioCryst Pharmaceuticals Inc and owns about 45,000 shares of BioCryst Pharmaceuticals Inc (BCRX) stock worth over $364,950. Details can be seen in Megan Sniecinski's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Megan Sniecinski has not made any transactions after 2019-11-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Megan Sniecinski

To

Megan Sniecinski Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Megan Sniecinski owns 1 companies in total, including BioCryst Pharmaceuticals Inc (BCRX) .

Click here to see the complete history of Megan Sniecinski’s form 4 insider trades.

Insider Ownership Summary of Megan Sniecinski

Ticker Comapny Transaction Date Type of Owner
BCRX BioCryst Pharmaceuticals Inc 2019-11-18 Chief Business Officer

Megan Sniecinski Latest Holdings Summary

Megan Sniecinski currently owns a total of 1 stock. Megan Sniecinski owns 45,000 shares of BioCryst Pharmaceuticals Inc (BCRX) as of November 18, 2019, with a value of $364,950.

Latest Holdings of Megan Sniecinski

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BCRX BioCryst Pharmaceuticals Inc 2019-11-18 45,000 8.11 364,950

Holding Weightings of Megan Sniecinski


Megan Sniecinski Form 4 Trading Tracker

According to the SEC Form 4 filings, Megan Sniecinski has made a total of 1 transactions in BioCryst Pharmaceuticals Inc (BCRX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in BioCryst Pharmaceuticals Inc is the acquisition of 45,000 shares on November 18, 2019, which cost Megan Sniecinski around $65,250.

Insider Trading History of Megan Sniecinski

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Megan Sniecinski Trading Performance

GuruFocus tracks the stock performance after each of Megan Sniecinski's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Megan Sniecinski is 72.06%. GuruFocus also compares Megan Sniecinski's trading performance to market benchmark return within the same time period. The performance of stocks bought by Megan Sniecinski within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Megan Sniecinski's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Megan Sniecinski

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 85.88 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 83.67 LIMIT LIMIT LIMIT LIMIT LIMIT

Megan Sniecinski Ownership Network

Ownership Network List of Megan Sniecinski

No Data

Ownership Network Relation of Megan Sniecinski

Insider Network Chart

Megan Sniecinski Owned Company Details

What does BioCryst Pharmaceuticals Inc do?

Who are the key executives at BioCryst Pharmaceuticals Inc?

Megan Sniecinski is the Chief Business Officer of BioCryst Pharmaceuticals Inc. Other key executives at BioCryst Pharmaceuticals Inc include Chief Financial Officer Anthony Doyle , Vice President and CCO Charles K Gayer , and VP & General Counsel & Corp Sec Alane P Barnes .

BioCryst Pharmaceuticals Inc (BCRX) Insider Trades Summary

Over the past 18 months, Megan Sniecinski made no insider transaction in BioCryst Pharmaceuticals Inc (BCRX). Other recent insider transactions involving BioCryst Pharmaceuticals Inc (BCRX) include a net purchase of 23,000 shares made by Helen M. Thackray , a net sale of 8,689 shares made by Machelle Sanders , and a net sale of 7,866 shares made by Nancy J Hutson .

In summary, during the past 3 months, insiders sold 8,600 shares of BioCryst Pharmaceuticals Inc (BCRX) in total and bought 0 shares, with a net sale of 8,600 shares. During the past 18 months, 43,853 shares of BioCryst Pharmaceuticals Inc (BCRX) were sold and 183,601 shares were bought by its insiders, resulting in a net purchase of 139,748 shares.

BioCryst Pharmaceuticals Inc (BCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

BioCryst Pharmaceuticals Inc Insider Transactions

No Available Data

Megan Sniecinski Mailing Address

Above is the net worth, insider trading, and ownership report for Megan Sniecinski. You might contact Megan Sniecinski via mailing address: 4505 Emperor Blvd., Suite 200, Durham Nc 27703.

Discussions on Megan Sniecinski

No discussions yet.